| Name | Title | Contact Details |
|---|
Atosa is a major manufacturer of commercial kitchen equipment, with a breadth of offering including refrigeration, cooking equipment, warming/holding equipment, stainless steel fabrication equipment, and much more. Atosas world-class manufacturing facilities and highly skilled employees, combined with innovative manufacturing procedures ensure that our customers always receive top-quality products at economical prices.
Polyram Plastic Industries Ltd is a leading international supplier of high-performance creative thermoplastic compounds, which used as raw materials in variety of markets. Polyram supplies both standard and customized thermoplastics in combination of glass fibers, glass beads and mineral fillers. The compounds are flame retardant, impact modified, heat stabilized, hydrolysis resistant and UV stabilized, with many other modifications available upon request. Polyram conforms to the highest quality control standards such as ISO/TS 16949 the internationally recognized standard of the automotive industry; NSF-61 & WRAS drinking water standards; and UL94 flammability standard. Polyrams focus is providing superior service and products for helping their customers develop and manufacture some of the most widely used products in the world.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.